🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Italy / NCT06528821
Active, not recruiting Observational

AI-Powered ECG Detecting Culprit Vessel Blood Flow Abnormality in ACS

NCT06528821 · tracked via the Priya Life Science Italy tracker
Sponsor
Powerful Medical
Phase
Observational
Started
2024-12-10
Last updated
2026-03-20

Condition(s) studied

Acute Coronary SyndromeSTEMICoronary OcclusionCoronary SyndromeNSTEMINSTEMI - Non-ST Segment Elevation MI

Study summary

AI ECG TIMI is an investigator-initiated, international, and multicenter registry of acute coronary syndrome patients aimed to identify electrocardiographic findings detected by an AI model predicting coronary blood flow alteration. The aim of the study is to identify electrocardiographic findings detected by an automated artificial intelligence (AI) model that can predict coronary blood flow alteration as assessed by the TIMI grade flow at the very moment of the invasive coronary angiography in patients with acute coronary syndromes.

Eligibility

Sex
ALL
Min age
18 Years
Max age
85 Years
Healthy volunteers
No
Inclusion Criteria: * Patients with acute coronary syndromes undergoing invasive coronary angiography as clinically indicated. * Availability of a standard 12-lead ECG performed at invasive coronary angiogram before percutaneous coronary intervention (maximum within 15 min before vascular access). * Age ≥18 years. Exclusion Criteria: * Individuals presenting for a non-emergent (elective) cardiac catheterization. * Individuals presenting with chronic coronary syndrome (CCS) or stable angina symptoms. * Individuals without symptoms suspicious for acute coronary syndromes. * Individuals with contraindications for cardiac catheterization.

Primary outcome measure(s)

Trial sites (9)

FacilityCityRegionStatus
LKH Hochsteiermark, Standort Bruck Bruck an der Mur Austria
LKH II Standort West Graz Austria
Medical University of Graz Graz Austria
OLV Aalst Aalst Belgium
AZ Sint Jan Bruges Belgium
Jessa Ziekenhuis Hasselt Belgium
University Hospital D'Annunzio Chieti Chieti Italy
San Pietro Hospital Rome Italy
Sant´Andrea Hospital Rome Italy

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06528821 on ClinicalTrials.gov ↗ ← All trials in Italy